PreciseDx
- 22/08/2024
- Series B
- $20,700,000
PreciseDx® is innovating oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven, disease analysis. Combining AI with our patented Morphology Feature Array® (MFA), PreciseDx provides access to unmatched disease insights and accurate, actionable intelligence for more comprehensive decision-making throughout the cancer care continuum.
- Industry Medical and Diagnostic Laboratories
- Website https://precisedx.ai/
- LinkedIn https://www.linkedin.com/company/precisedx/
Related People
Wayne BrinsterFounder
Serially Successful CEO – Diagnostics, Devices, Life Sciences - Strategic Executive Leader with 19+ years of driving revenue and promoting transformation within Diagnostics, Life Science and Biotech industry
Throughout my career as a vision-driven, goal-focused executive I have built a solid track record of improving processes and procedures balancing focus across business development, maximizing revenues and returns, harnessing team strengths, and building consensus among executives and stakeholders.
Proven track record of multimillion-dollar revenue growth, rapid operational turn around, and “right-fit” operational infrastructure that grow with the organization. A trusted partner to Board Leadership and relied upon to identify and capitalize on opportunities with an ability to think out of the box and build an environment of innovation have enabled me to form a well-earned reputation for delivering consistent improvements to the success of the organization.